trending Market Intelligence /marketintelligence/en/news-insights/trending/svX54AvZ60H7cxVdQbrd2Q2 content esgSubNav
In This List

Opexa Therapeutics completes merger with Acer Therapeutics

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Opexa Therapeutics completes merger with Acer Therapeutics

Opexa Therapeutics Inc. completed its merger with private pharma company Acer Therapeutics Inc.

Acer Therapeutics shareholders now own 88.8% of the combined company's outstanding common stock, with the remaining 11.2% owned by Opexa shareholders.

The combined company, renamed Acer Therapeutics Inc., will start trading Sept. 21 on the Nasdaq Capital Market under the symbol ACER.

Additionally, an investor group led by TVM Capital Life Sciences invested about $15.7 million in Acer Therapeutics before the deal closed.